Phase Ib Study of Chiauranib in Patients With Ovarian Cancer
NCT03166891
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
25
Enrollment
INDUSTRY
Sponsor class
Conditions
Ovarian Cancer
Interventions
DRUG:
Chiauranib
Sponsor
Chipscreen Biosciences, Ltd.